Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752596 · ClinicalTrials.gov registry record · Phase 2
Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00752596: Completed Phase 2 study, sponsored by Forest Laboratories.
NCT00752596 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00752596, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.
Interventions
- DRUG Azimilide 2HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
What the finished NCT00752596 record still lists
NCT00752596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Azimilide 2HCl is the first listed.
NCT00752596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00752596 about?
NCT00752596 is a clinical study titled "Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient". This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.
What is the current status of trial NCT00752596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2005-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00752596?
The interventions under investigation include: Azimilide 2HCl (DRUG).
Who is sponsoring clinical trial NCT00752596?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00752596's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia